Nazli Hossain1, Fatima H Kanani, Shabana Ramzan, Robina Kausar, Shabana Ayaz, Rafiq Khanani, Lubna Pal. 1. Department of Obstetrics and Gynecology Unit II (N.H., S.R., R.K., S.A.), and Department of Pathology and Microbiology (R.K., F.H.K.), Dow Diagnostics and Reference Laboratory, Dow International Medical College, Dow University of Health Sciences, Dow University of Health Sciences, Karachi 74200, Pakistan; Program for Polycystic Ovarian Syndrome (L.P), Program for Reproductive Aging and Bone Health (L.P.), and Yale Reproductive Endocrinology, Department of Obstetrics, Gynecology, and Reproductive Sciences (L.P.), Yale University School of Medicine, New Haven, Connecticut 06520.
Abstract
OBJECTIVE: The objective of the study was to determine whether vitamin D (vitD) supplementation during pregnancy affects obstetric and neonatal outcomes. SETTING: The study was conducted at a university hospital in Karachi, Pakistan. METHODS: The study was a single-center, open-label, randomized, controlled trial of routine care (group A, 200 mg ferrous sulfate and 600 mg calcium daily) vs vitD supplementation (group B, 4000 IU vitamin D3 daily), started at 20 weeks and continued till delivery. Maternal serum samples of 25-hydroxyvitamin D (25OHD) were collected at baseline and delivery. Neonatal vitD status was assessed in cord blood or in neonatal serum samples within 48 hours of birth. Obstetric outcomes included gestational hypertension, gestational diabetes, and preterm labor, and neonatal well-being included small for gestational age, birth weight, length, head circumference, and 1- and 5-minute Apgar scores. RESULTS:Of 207 gravidae enrolled, 193 completed the trial. Maternal age, vitD status, and gestational age at enrollment were comparable between the two groups. At delivery, maternal 25OHD was increased in group B (18.3 ± 11 ng/dL vs 8.82 ± 11.84 ng/dL (P = .001) compared with group A (6.9 ± 7.0 ng/dL vs 6.32 ± 3.97 ng/dL, P = .06). The obstetric outcomes were comparable between the two groups (P > .05). Neonatal 25OHD levels were significantly higher in group B compared with group A (19.22 ± 12.19 ng/dL vs 6.27 ± 5.2 ng/dL). There was positive correlation between maternal and neonatal 25OHD levels (r = 0.83, P = .001). One- and 5-minute Apgar scores were significantly higher in group B (7.10 ± 0.66 vs 6.90 ± 0.50, P = .026, and 8.53 ± 0.68 vs 8.33 ± 0.81, P = .051, respectively). Neonatal anthropometric parameters were comparable between the two groups (P > .05). CONCLUSION:Maternal vitD supplementation improved maternal and neonatal vitD status.
RCT Entities:
OBJECTIVE: The objective of the study was to determine whether vitamin D (vitD) supplementation during pregnancy affects obstetric and neonatal outcomes. SETTING: The study was conducted at a university hospital in Karachi, Pakistan. METHODS: The study was a single-center, open-label, randomized, controlled trial of routine care (group A, 200 mg ferrous sulfate and 600 mg calcium daily) vs vitD supplementation (group B, 4000 IU vitamin D3 daily), started at 20 weeks and continued till delivery. Maternal serum samples of 25-hydroxyvitamin D (25OHD) were collected at baseline and delivery. Neonatal vitD status was assessed in cord blood or in neonatal serum samples within 48 hours of birth. Obstetric outcomes included gestational hypertension, gestational diabetes, and preterm labor, and neonatal well-being included small for gestational age, birth weight, length, head circumference, and 1- and 5-minute Apgar scores. RESULTS: Of 207 gravidae enrolled, 193 completed the trial. Maternal age, vitD status, and gestational age at enrollment were comparable between the two groups. At delivery, maternal 25OHD was increased in group B (18.3 ± 11 ng/dL vs 8.82 ± 11.84 ng/dL (P = .001) compared with group A (6.9 ± 7.0 ng/dL vs 6.32 ± 3.97 ng/dL, P = .06). The obstetric outcomes were comparable between the two groups (P > .05). Neonatal 25OHD levels were significantly higher in group B compared with group A (19.22 ± 12.19 ng/dL vs 6.27 ± 5.2 ng/dL). There was positive correlation between maternal and neonatal 25OHD levels (r = 0.83, P = .001). One- and 5-minute Apgar scores were significantly higher in group B (7.10 ± 0.66 vs 6.90 ± 0.50, P = .026, and 8.53 ± 0.68 vs 8.33 ± 0.81, P = .051, respectively). Neonatal anthropometric parameters were comparable between the two groups (P > .05). CONCLUSION: Maternal vitD supplementation improved maternal and neonatal vitD status.
Authors: Spyridon N Karras; Hana Fakhoury; Giovanna Muscogiuri; William B Grant; Johannes M van den Ouweland; Anna Maria Colao; Kalliopi Kotsa Journal: Ther Adv Musculoskelet Dis Date: 2016-07-13 Impact factor: 5.346
Authors: S Karras; S A Paschou; E Kandaraki; P Anagnostis; C Annweiler; B C Tarlatzis; B W Hollis; W B Grant; D G Goulis Journal: Eur J Clin Nutr Date: 2016-03-02 Impact factor: 4.016
Authors: J Wen; Q Hong; L Zhu; P Xu; Z Fu; X Cui; L You; X Wang; T Wu; H Ding; Y Dai; C Ji; X Guo Journal: Int J Obes (Lond) Date: 2016-12-23 Impact factor: 5.095